Other languages Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Market Closed - Nyse Other stock markets 01:30:02 27/04/2024 am IST			5-day change	1st Jan Change
18.01 ^USD	+32.43%		+79.03%	-3.69%

01/04	Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	CI
29/03	Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	01/04
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03
Top Midday Gainers	20/03
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease	20/03
Annovis Bio Shares Fall After Downgrade From Brookline Capital	29/02
Annovis Bio Completes Phase 2 Study of Alzheimer's Treatment Candidate	14/02
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease	14/02
Annovis Bio, Inc. Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company?s Portfolio	30/01
Sector Update: Health Care Stocks Sliding Late Afternoon	25/01
Top Midday Decliners	25/01
Sector Update: Health Care Stocks Softer Wednesday Afternoon	25/01
Annovis Bio Postpones Data Release for Parkinson's Treatment Trial -- Shares Fall	24/01
Annovis Bio, Inc. Refines Timeline for Parkinson's Phase III Study Data Announcement	24/01
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase III Study of Buntanetap in Parkinson?s Disease	05/12
Sector Update: Health Care Stocks Ease in Late Afternoon	28/11
Sector Update: Health Care Stocks Softer Monday Afternoon	28/11
Sector Update: Health Care	28/11
Annovis Bio Says Enrollment in Phase 2/3 Alzheimer's Disease Trial Exceeds Projections; Shares Rise	27/11
Annovis Bio, Inc. Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projects	27/11
Annovis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Other languages

Filters